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Objective To measure the effect of low dose systemic glucocorticoid treatment on 
the adrenal response to ACTH in patients with rheumatoid arthritis (RA). 
Methods Patients with RA who took part in a double blind randomized placebo 
controlled trial of budesonide (3mg daily and 9 mg daily) and prednisolone (7.5 mg 
daily) had a short (60 minute) synacthen test at baseline and the day after 
completing the three months treatment programme. Plasma cortisol measurements 
were compared from baseline to three months within and between the treatment 
groups. Individual patients were classified as normal or abnormal responders to 
ACTH if changes were more than 2 standard deviations below the values found in 
all the patients taken together before treatment.  
Results Short synacthen tests were carried out on 139 patients before they 
commenced study medication and on 134 after cessation. There were no changes 
in the placebo group. Mean plasma cortisol following treatment was reduced in all 
treatment groups. In addition, mean values were significantly reduced for the 30-
minute and 60-minute responses to synacthen.  The maximum reduction (35%) 
occurred in the prednisolone group at 60 minutes. Following treatment, 34% of 
patients taking budesonide 9 mg and 46% taking prednisolone 7.5 mg fail to reach 
the normal maximum cortisol response to ACTH. Four patients failed to achieve 
the normal percentage increase in cortisol, but only one patient failed to attain both 
criteria. 
Conclusion Low doses of a glucocorticoid result in depression of baseline and 
synacthen stimulated cortisone levels after 12 weeks of therapy. Although, the 
responsiveness of the HPA axis in individual patients generally remains within the 
normal range, these changes should be investigated further. 
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Glucocorticoids have been used to treat rheumatoid arthritis (RA) ever since they 
first became available for use in humans in 1948 (1). Clinical experience suggests 
that it often is difficult to withdraw glucocorticoids (2). A number of other reports   
deal with suppression of the of hypothalamic-pituitary-adrenal (HPA) axis in RA 
patients taking glucocorticoids. In 1961 Shuster and Williams (3) showed that RA 
patients taking low doses of cortisone (25mg daily) had normal adrenal response to 
a pyrogen and to corticotrophin, but a small proportion of those taking 37.5 to 50 
mg cortisone daily had a reduced response. Treadwell and colleagues (4) 
surveyed HPA function in 41 patients (38 with RA) taking long-term prednisolone, 
and found normal responses in those taking 7.5 mg daily or less, who had also 
been on therapy for less than 30 months. In contrast, many patients on higher 
doses, who had also been on treatment for longer, showed a reduced response to 
metyrapone. After the short synacthen test was developed (5) it was applied in RA 
patients and shown to work satisfactorily (6). One third of patients taking long term 
glucocorticoids had a reduced HPA response, but no details of doses were 
provided. In a study of 19 patients taking a wide range of glucocorticoid doses for 
differing lengths of time, Jasani (7) found that 6 had a subnormal response to 
synacthen compared to RA patients who had never taken glucocorticoids. A further 
study by Hicklin and Wills (8) identified deficiencies in HPA response in some 
patients who had been taking a variety of doses of glucocorticoid for at least 12 
months. 
 
These studies have some common characteristics: they compared patients who 
had been treated with glucocorticoids to those who had not; most of the patients 
had received more than low dose treatment (prednisolone 7.5mg or less (9)); and 
there was a proportion of patients amongst those with higher dose and longer 
duration treatment who showed deficiencies in their HPA axis response. Thus 
while the results taken together raise the suspicion that some HPA suppression 
may occur in some patients with low dose treatment, they cannot provide definitive 
evidence for the severity or frequency of such deficiencies. In 1976 Chamberlain 
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and Keenan (10) performed a 30 min synacthen test on 41 patients who had taken 
placebo, prednisolone 3mg daily or prednisolone 5mg daily for 2 years. They 
reported as mild supression in the HPA axis. It is remarkable that in the intervening 
years, no further investigations seem to have addressed an issue, which is of 
considerable importance in weighing the benefits of glucocorticoid treatment 
against the risks. Therefore, as part of a multi-centre, double-blind, randomized, 
placebo-controlled, 12-week trial of two types of glucocorticoid in RA (11), we 
investigated HPA axis function by conducting short synacthen tests before and 
immediately after treatment.  
 
 
Patients and Methods 
 
Patients and treatment: Following research ethics committee approval, patients 
with rheumatoid arthritis, as defined by the ACR criteria (12) and with onset of 
disease over 16 years of age, were recruited to the study (11) from 16 centres in 
the United Kingdom, Belgium and Sweden. All had active disease as shown by 
early morning stiffness equal to or greater than 45 minutes and at least 6 tender 
joints, of which at least 3 had associated soft tissue swelling. Patients were either 
on no treatment or stable doses of non-steroidal anti-inflammatory and/or disease-
modifying anti-rheumatic drugs. No glucocorticoids had been given by any route for 
at least 30 days.  
 
The primary purpose of the trial was to test the efficacy of budesonide, a 
glucocorticoid that is 90% metabolized during first pass through the liver (13,14), 
and is generally used in a controlled release capsule to treat inflammatory bowel 
disease (15). A 9mg oral dose is considered equivalent to a systemic 
glucocorticoid dose equivalent to approximately 7.5 mg prednisolone. Subjects 
were randomized to receive budesonide CIR 3mg, budesonide CIR 9mg, 
prednisolone 7.5mg or placebo once daily. Treatment was continued for 12 weeks. 
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Adherence to the dosing instructions was checked at 2, 4, 8 and 12 weeks by 
patient interview and counting returned packs of medication. Patients taking 
<=80% of the treatment, or missing study medication for >= 3 consecutive days 
were considered non-adherent. Further details of inclusion and exclusion criteria, 
together with data relating to treatment efficacy, have been reported elsewhere 
(11). 
 
Measurement of adrenal function: Measurement of adrenal function was performed 
at baseline and after 12 weeks using the short ACTH (synacthen) stimulation test. 
Venous samples were taken for serum cortisol estimation before, 30 and 60 
minutes after an intra-muscular injection of 250mcg synacthen. Cortisol 
concentrations were measured by a gas chromatography mass spectrometry 
method to avoid cross-reactivity with the exogenous steroid (16). Post-treatment 
samples were taken 24 hours after the last treatment dose and all samples were 
taken at 9am.  
 
Statistical analysis: The mean values and 95% confidence intervals (CI) 
concentrations of serum cortisol and the mean and 95% CI change in response to 
ACTH were calculated for each group before and after treatment, and were 
compared using the paired t-test within groups and the unpaired t-test between 
groups. Log(10) transformation was used for the change scores to allow for a 
nonparametric distribution.  
 
Individual patients were classified as normal or abnormal responders to ACTH 
according to their initial, final and change values of serum cortisol following ACTH 
administration. Abnormal levels were defined as those more than 2 standard 









143 patients were randomized to the four treatment groups. One did not receive 
study medication and was excluded from the analysis. Patient demographics are 
shown in Table 1. Short synacthen tests were carried out on 139 patients before 
they commenced study medication and on 134 after cessation. 
 
Mean plasma cortisol concentrations in the synacthen tests before and after 
treatment are shown in Table 2 and illustrated in Figure 1. There were no 
significant differences between groups before treatment for baseline, 30-minute 
and 60-minute measurements. In the placebo group plasma cortisol did not change 
following 12 weeks treatment with the trial medication, nor were the 30-minute and 
60-minute concentrations in response to synacthen significantly changed. However 
the mean plasma cortisol concentration following treatment was reduced in all 
treatment groups. In addition, mean values were significantly reduced for the 30-
minute and 60-minute responses to synacthen.  For budesonide 3mg the 
reductions at baseline, 30mins and 60 mins were 14%, 16% and 13%; for 
budesonide 9mg reductions were 26%, 33% and 34%; for prednisolone 7.5mg 
reductions were 28%,34% and 35%; and for placebo reductions were 5%, 1% and 
0 (P<0.05 for all values except placebo group)..  
 
Table 3 shows the results when patients were individually classified as being 
abnormal if they had a plasma cortisol concentration more than 2 standard 
deviations below the pre-treatment values for all the patients taken together. At 
each of the time points of the ACTH test there was a proportion of patients in the 
budesonide 9 mg and prednisolone 7.5 mg treatment groups which had lower 
plasma cortisol.  
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Because some patients attained maximum plasma cortisol concentration before 60 
minutes, the maximum of the 30-minute and 60-minute plasma cortisol 
concentrations was taken as the maximum response to ACTH. The mean value for 
pre-treatment patients was 787 nmol/L with a standard deviation of 161. Patients 
were individually classified as being abnormal for maximum plasma cortisol if they 
had a concentration more than 2 standard deviations below the pre-treatment 
maximum values for all the patients taken together (i.e. less than 465 nmol/L). The 
maximum response to ACTH was also used to calculate the percentage increase 
in plasma cortisol for each patient. The results had a skewed distribution, which 
was corrected by log(10) transformation. The mean and standard deviation of the 
transformed values were 2.04 and 0.25, the lower limit of normal was taken as the 
mean minus 2 standard deviations, and the resultant value transformed back to 
give an increase of 35% as the minimum acceptable normal value.  
 
The numbers of patients falling below the lower limit of normal for: baseline plasma 
cortisol; maximum plasma cortisol after ACTH injection; the normal percentage 
increase, and below various combinations of all three measures are shown in 
Table 4. Following treatment, a substantial proportion of patients taking 
budesonide 9 mg (34%) or prednisolone 7.5 mg (46%) fail to reach the normal 
maximum cortisol concentration after stimulation by ACTH. A few patients fail to 
achieve the normal percentage increase in cortisol, but only one patient (taking 
budesonide 9 mg) fails to attain both criteria. Thus, all patients with low baseline 
cortisol following the study treatment were able to mount a satisfactory relative 
increase in response to ACTH so that they attained a maximum cortisol 
concentration or a percentage increase in plasma cortisol that was within the 
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This randomized, placebo-controlled trial of budesonide (3mg and 9mg daily) and 
prednisolone (7.5mg daily) showed a dose-dependent reduction in the HPA response to 
the synacthen test in patients with moderately active rheumatoid arthritis. For prednisolone 
7.5mg daily the mean reduction in maximum production of cortisol in response to ACTH 
was 35%. However, almost all patients who, following glucocorticoid therapy, failed to 
achieve a normal percentage increase in cortisol in response to ACTH did achieve 
maximum plasma cortisol levels within the normal range. Thus it is clear that even low 
doses of a glucocorticoid result in measurable depression of baseline and synacthen 
stimulated cortisone levels after 12 weeks of therapy. However, all patients were able to 
respond to ACTH by increasing their plasma concentrations of cortisol, and those who 
achieved a lower than normal percentage response still achieved an absolute value within 
the normal range. For comparison with normal subjects the median (5th-95th percentile 
values) in 100 healthy volunteers were: baseline, 349(164-870); 30 min, 811 (626-1431); 
60 min, 972 (766-1655); 0-30min, 488 (289-776); 0-60 min, 645 (433-1063) (17). 
 
There is some evidence from clinical studies that in patients with RA there is a 
blunting of the diurnal rhythm of hormonal secretion compared to patients with 
chronic osteomyelitis (18). Patients with rheumatoid arthritis also have a blunted 
cortisol response to the stress of surgery (19) and impaired cortisol secretion in the 
presence of intact ACTH secretion consistent with relative adrenal glucocorticoid 
insufficiency has also been reported (20). However, patients with new onset RA 
have morning levels of ACTH and cortisol that are similar to normal age- and sex-
matched controls (21,22). A review of the literature concluded that most studies 
have not revealed major differences in HPA axis activity in patients with RA 
compared with that in control individuals (23). However, subtle differences may 
exist that influence the time course or severity of inflammation. Crofford and 
Glucocorticoids and the ACTH test in RA 
Page 9 
colleagues (22) have suggested that the normal serum ACTH and cortisol they 
measured in RA patients was inappropriately low, considering the levels of joint 
inflammation and raised plasma IL-6. Another study employed the 
dexamethasone-CRF test to explore HPA control mechanisms in RA (24). 
Dexamethasone taken 18 hours before an intravenous injection of CRF completely 
suppresses the ACTH and cortisol response in normal controls, but three of seven 
patients with active RA were able to escape from this feedback control mechanism. 
This suggests that there may be a subpopulation of patients with RA who have 
impaired glucocorticoid feedback. 
 
The synacthen test has been used as an estimate of the HPA response to stress 
since it was first developed. However, other stressors, such as insulin 
hypoglycaemia (10, 25) or the administration of pyrogen (3), have been found to 
produce a normal response in patients taking glucocorticoids (for a variety of 
reasons) who had a reduced response to ACTH (25). Thus it is not clear that the 
reduction in response to ACTH following low dose prednisolone revealed in the 
present study is of physiological significance. Another question is whether the 
reduced response to ACTH is recovered quickly. In 14 patients who had been 
taking high doses of prednisone (up to 100mg/m2/day) for up to 29 days there was 
a clear suppression of adrenal function, but in the large majority of these patients 
the HPA axis response was restored in less than 7 days (26). A further study of 75 
patients who received at least 25 mg prednisone daily for up to 30 days found that 
half had a reduced response to CRF on the day after stopping treatment. All but 2 
of these patients recovered ACTH function within 2 weeks. (27). It seems likely that 
recovery from the less marked suppression induced by low dose glucocorticoids 
would be at least equally rapid, but further measurements will be required to 
confirm this. An entry requirement for this study was no glucocorticoids in the 
preceding 30 days. It is possible that some patients received glucocorticoids before 
then (we did not record that information) but it seems unlikely that this would have 
affected our results. 
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Low dose oral prednisolone therapy has attracted added interest in recent years 
following the recognition that this therapy can prevent the joint destruction of RA 
(28). The present data show that low doses of a glucocorticoid result in depression 
of baseline and synacthen stimulated cortisone levels after 12 weeks of therapy. 
Although the responsiveness of the HPA axis in individual patients generally 
remains within the normal range, these changes should be investigated further. 
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Table 1. Patient characteristics (mean values or proportions). 









N  37 35 39 31 142 
Age (years)  54.2 57.8 53.4 54.7 55.0 
Proportion Female (%)  70 77 62 77 71 
Weight (Kg)  73.5 74.6 73.9 71.4 73.4 
Height (cm)  166 165 168 166 166 
Disease Duration (years)  13.1 8.5 7.0 7.2 9.0 
Proportion with erosions (%)  84 66 54 87 72 
Number taking NSAIDs   30 27 30 26 113 
Number taking DMARDs   28 25 26 20 99 
Disability (HAQ) Score   Baseline 1.61 1.57 1.51 1.52 1.55 
Disability (HAQ) Score   12 weeks 1.57 1.41 1.11 1.48  
Tender joint count Baseline 14.2 11.8 12.3 12.6 12.7 
Tender joint count 12 weeks 11.0 7.7 6.6 11.7  
Swollen joint count Baseline 12.9 9.8 11.6 11.8 11.5 
Swollen joint count 12 weeks 10.2 6.2 7.2 11.5  
Patient's assessment of pain (mm) Baseline 54.1 65.5 49.2 56.9 56.22 
Patient's assessment of pain (mm) 12 weeks 47.9 47.6 28.8 54.8  
Patient's global* Baseline 50.6 59.0 54.4 54.4 54.54 
Patient's global* 12 weeks 48.1 42.4 31.8 55.8  
Clinician’s global** Baseline 3.1 3.2 3.0 3.1 3.1 
Clinician’s global** 12 weeks 2.8 2.7 2.3 3.0  
Early morning stiffness (minutes) Baseline 111 98 93 105 102 
Early morning stiffness (minutes) 12 weeks 54 73 73 94  
CRP (mg/L) Baseline 22.5 32.9 30.2 39.9 28.8 
CRP (mg/L) 12 weeks 21.0 33.3 10.8 34.2  
*Patient's global assessment of disease activity  ** Clinician’s global assessment of disease activity 
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Table 2. Mean (96% CI) plasma cortisol concentrations (nmol/L) during the ACTH test for patients before and after treatment. 
 
Occasion Medication N 
  Time after ACTH injection 
 Baseline  30 mins  60 mins 
 Mean 95% CI  Mean 95% CI  Mean 95% CI 
Before Treatment Budesonide 3 mg 37  397 (341, 453)  672 (619, 726)  743 (679, 807)  
 Budesonide 9 mg 34  387 (344, 429)  711 (664, 758)  821 (767, 875)  
 Prednisolone 7.5 mg 38  348 (318, 378)  674 (634, 714)  786 (737, 835)  
 Placebo 30  366 (311, 422)  695 (642, 749)  790 (738, 842)  
             
After Treatment Budesonide 3 mg 36  341 (297, 393) **b 565 (514, 616) ***bc 646 (594, 698) *a, ***bc 
 Budesonide 9 mg 32  286 (228, 344)  479 (401, 557) ***d 545 (467, 622) ***d 
 Prednisolone 7.5 mg 37  251 (208, 295) **e 443 (394, 491) ***e 511 (456, 565) ***e 
  Placebo 29   349 (296, 402)   690 (639, 740)   788 (736, 840)  
            
*P<0.05, **P<0.01, ***P<0.001; a Budesonide 3 mg vs. Budesonide 9 mg; b Budesonide 3 mg vs. Prednisolone 7.5 mg; c 
Budesonide 3 mg vs. Placebo; d Budesonide 9 mg vs. Placebo; e Prednisolone 7.5 mg vs. Placebo 
 









Time after ACTH injection 
Before Treatment  After Treatment 
Baseline 30 mins 60 mins  Baseline 30 mins 60 mins 
Budesonide 3 mg 0 (0) 1 (3) 2 (5)  1 (3) 4 (11) 3 (8) 
Budesonide 9 mg 0 (0) 0 (0) 0 (0)  7 (21) 11 (34) 11 (34) 
Prednisolone 7.5 mg 0 (0) 1 (3) 1 (3)  5 (14) 14 (38) 14 (38) 
Placebo 1 (3) 1 (3) 1 (3)   0 (0) 0 (0) 0 (0) 
 




Table 4. Number (%) of patients failing to meet 'normal' criteria for change in plasma cortisol following ACTH 
injection. 
 


















Before Treatment Budesonide 3 mg 0 (0) 1 (3) 4 (11) 0 (0) 0 (0) 0 (0) 5 (14) 0 (0) 
 Budesonide 9 mg 0 (0) 0 (0) 1 (3) 0 (0) 0 (0) 0 (0) 1 (3) 0 (0) 
 Prednisolone 7.5 mg 0 (0) 1 (3) 0 (0) 0 (0) 0 (0) 0 (0) 1 (3) 0 (0) 
 Placebo 1 (3) 1 (3) 1 (3) 1 (3) 0 (0) 0 (0) 2 (7) 0 (0) 
          
After Treatment Budesonide 3 mg 1 (3) 3 (8) 0 (0) 0 (0) 0 (0) 0 (0) 3 (8) 0 (0) 
 Budesonide 9 mg 7 (21) 11 (34) 3 (9) 6 (19) 0 (0) 1 (3) 14 (44) 0 (0) 
 Prednisolone 7.5 mg 5 (14) 17 (46) 1 (3) 4 (11) 0 (0) 0 (0) 17 (47) 0 (0) 
  Placebo 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 
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Figure 1. Changes (mean and 95% confidence intervals) in plasma cortisol during the ACTH 
test before and after treatment with placebo, budesonide 3mg, budesonide 9mg and 
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